INS and type 2 diabetes mellitus: We have identified that targeting the FTO/m6A axis could significantly improve insulin secretion in non-diabetic mouse and human pancreatic islets, suggesting that targeting FTO signaling by effective inhibitors such as bisantrene could be relevant for T2D therapy.